“I’m Home(screen)!”: Social Media in Health Care Has Arrived Laura Housman Peer reviewed publication: Clinical Therapeutics Nov 2017, Volume 39, Issue 11, Pages 2189–2195, DOI:http://dx.doi.org/10.1016/j.clinthera.2017.10.007
Insurers Turn to Automated Prior Authorization Programs to Rein in Genetic Testing Use Turna Ray, author (interviewed and quoted) GenomeWeb 2017 Aug 21
Loxo's larotrectinib likely to drive need for panel testing of tumors; but adoption time, reimbursement present challenges Alaric DeArment, author (interviewed and quoted) BioPharm Insight (Syndicated Research) 2017 July 28
Strategies for Integrating Personalized Medicine into Clinical Practice Daryl Pritchard, Franziska Moeckel, Marysusan Villa, Laura Housman, Catherine McCarty, and Howard L. McLeod Peer reviewed publication: Personalized Medicine March 2017 ,Vol. 14, No. 2, Pages 141-152, DOI 10.2217/pme-2016-0064
Can and should value-based pricing be applied to molecular diagnostics? Martina Garau, Adrian Towse, Louis Garrison, Laura Housman, Diego Ossa Peer reviewed publication: Personalized Medicine January 2013, Vol. 10, No. 1, Pages 61-72 , DOI 10.2217/pme.12.99
Innovative tests for patient-tailored treatments: demonstrating value in the age of personalized medicine Peer reviewed publication: Personalized Medicine March 2011, Vol. 8, No. 2, Pages 183-189 , DOI 10.2217/pme.10.90
Palmetto Draft LCD of Cancer Genomic Profiling in NSCLC is Good First Step, Say NGS Test Providers Turna Ray, author (interviewed and quoted) GenomeWeb 2015 Feb 2 https://www.genomeweb.com/reimbursement/palmetto-draft-lcd-cancer-genomic-profiling-nsclc-good-first-step-say-ngs-test
Employee Benefits Today And Tomorrow: What The Future Looks Like Susan Scutti, author (interviewed and quoted) Medical Daily 2014 Nov 20 http://www.medicaldaily.com/employee-benefits-today-and-tomorrow-what-future-looks-311466
To Test or Not to Test Ed Silverman, author (interviewed and quoted) Biotechnology Healthcare 2004 Sep; 1(4): 30-35,44
Presentations Partial listing
"Direct to Wallet and New Paradigms in Access to NGS Testing" on February 15, 2018 at the Molecular Medicine Tri-Conference by Cambridge Healthech Institute (San Francisco, CA)
"Enter Your Payment Information Here: Patient Contributions toward Next-Generation Sequencing Testing in Today's Reimbursement Environment" on August 15, 2017 at theNext Generation Diagnostics Summit by Cambridge Healthtech Institute (Washington, D.C.)
“Direct to Wallet: Understanding and Managing Patient Responsibilities associated with Next Generation Sequencing Testing in Today's Reimbursement Environment” on August 23, 2016 at the Next Generation Diagnostics Summit by Cambridge Healthtech Institute (Washington, D.C.)
“Communication: The Third “C” in Commercialization” on July 7, 2016 at the Precision Medicine program within the Molecular Diagnostics Summit 2016 by GTC (Boston, MA)
Conference Chair and Moderator, July 8, 2016, the Molecular Diagnostics Summit 2016 by GTC (Boston, MA)
“Patient as Payor:The New Frontier in Access to Innovation” on April 8 2016 at the ASU Sandra Day O’Connor College of Law Center for Law, Science & Innovation 5th Regulatory and Reimbursement Molecular Diagnostics Workshop (Scottsdale, AZ)
“Exploring the Intersection of Precision Medicine and Population Health:Avoiding a Zero Sum Game” on March 22 2016 at the Circulating Biomarker World Congress 2016 (Boston, MA)
“Clinical Innovations using Outcomes Data” on January 27 2016 at the Personalized Medicine World Congress 2016 (Mountain View, CA)
“Health Systems Infrastructure and Information Challenges Related to Personalized Medicine” on October 14 2015 at the PMC/BIO Solutions Summit (Washington, DC)
“Reimbursement of Stand-Alone vs. Companion Molecular Tests” onNovember 18 2014 at the Evidence Based Reimbursement Summit (Bethesda)
"Are They Worth It? Assessing the Value of Targeted Therapies and Companion Diagnostics" on June 25 2014 at the Biotechnology Industry Organization's2014 International Convention. (San Diego)
“Regulatory & Reimbursement Trends in Biomarker Development”, March 21 2014 at the GTC Biomarker Summit (San Diego)
“Weighing Options:Reimbursement Roadmap When Clinical Data is Scarce” 5th Annual Diagnostic Coverage & Reimbursement Conference (Dec 9, 2013 (Boston); Feb 24, 2014 (San Diego))
“Leaning In:Successful Strategies as a Manufacturer to Engage Payers in Diagnostic Technology Assessment and Coverage” Evidence-Based Reimbursement Summit, Oct 22 2013 (Philadelphia)
“Entrepreneurial Approaches to Challenges in Healthcare” Boston University School of Public Health Fall Forum, September 27 2013 (Boston)
“How Payers and Patients Impact Medical Product Development” Healthcare Businesswomen’s Association (HBA) meeting, February 26 2013 (Genzyme Center, Boston)
“Creating and Applying Successful Strategies for Diagnostic Coverage and Reimbursement”, Evidence-Based Reimbursement Summit, Nov 5 2012 (Philadelphia)